Sanofi SA

Press Release: Availability of the Q1 2023 Memorandum for modelling purposes

30 Mar 2023 00:30:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 

23 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 

21 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

18 Mar 2023 09:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

16 Mar 2023 15:06:44 By Nasdaq GlobeNewswire

Information concerning the total number of voting rights and shares – February 2023

14 Mar 2023 13:27:20 By Nasdaq GlobeNewswire

Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

13 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

07 Mar 2023 00:00:00 By Nasdaq GlobeNewswire

Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A

02 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

24 Feb 2023 10:16:47 By Nasdaq GlobeNewswire